Abstract:Transcriptionally latent forms of replication-competent proviruses, present primarily in a small subset of memory CD4 + T cells, pose the primary barrier to a cure for HIV-1 infection because they are the source of the viral rebound that almost inevitably follows the interruption of antiretroviral therapy. Over the last 30 years, many of the factors essential for initiating HIV-1 transcription have been identified in studies performed using transformed cell lines, such as the Jurkat T-cell model. However, as highlighted in this review, several poorly understood mechanisms still need to be elucidated, including the molecular basis for promoter-proximal pausing of the transcribing complex and the detailed mechanism of the delivery of P-TEFb from 7SK snRNP. Furthermore, the central paradox of HIV-1 transcription remains unsolved: how are the initial rounds of transcription achieved in the absence of Tat? A critical limitation of the transformed cell models is that they do not recapitulate the transitions between active effector cells and quiescent memory T cells. Therefore, investigation of the molecular mechanisms of HIV-1 latency reversal and LRA efficacy in a proper physiological context requires the utilization of primary cell models. Recent mechanistic studies of HIV-1 transcription using latently infected cells recovered from donors and ex vivo cellular models of viral latency have demonstrated that the primary blocks to HIV-1 transcription in memory CD4 + T cells are restrictive epigenetic features at the proviral promoter, the cytoplasmic sequestration of key transcription initiation factors such as NFAT and NF-κB, and the vanishingly low expression of the cellular transcription elongation factor P-TEFb. One of the foremost schemes to eliminate the residual reservoir is to deliberately reactivate latent HIV-1 proviruses to enable clearance of persisting latently infected cells—the "Shock and Kill" strategy. For "Shock and Kill" to become efficient, effective, non-toxic latency-reversing agents (LRAs) must be discovered. Since multiple restrictions limit viral reactivation in primary cells, understanding the T-cell signaling mechanisms that are essential for stimulating P-TEFb biogenesis, initiation factor activation, and reversing the proviral epigenetic restrictions have become a prerequisite for the development of more effective LRAs.

Targeting noncoding RNAs to reactivate or eliminate latent HIV reservoirs

Identify Potential Regulators in Hiv-1 Latency by Joint Microrna and Mrna Analysis

Inactivation of Latent HIV-1 Proviral DNA Using Clustered Regularly Interspaced Short Palindromic Repeats/Cas9 Treatment and the Assessment of Off-Target Effects.

Development of an Attenuated Tat Protein as a Highly-effective Agent to Specifically Activate HIV-1 Latency

Identification of CD98 As a Novel Biomarker for HIV-1 Permissiveness and Latent Infection

Role of long noncoding RNA in regulating HIV infection—a comprehensive review

Transcriptomic study reveals alteration in the expression of long non-coding RNAs (lncRNAs) during reversal of HIV-1 latency in monocytic cell line

MicroRNAs and long non-coding RNAs during transcriptional regulation and latency of HIV and HTLV

The cell biology of HIV-1 latency and rebound

High-throughput Sequencing Identifies HIV-1-replication- and Latency-Related Mirnas in CD4+ T Cell Lines.

Long non-coding RNA uc002yug.2 activates HIV-1 latency through regulating mRNA level of various RUNX1 isoforms and increasing Tat expression.

Long Noncoding RNA uc002yug.2 Activates HIV-1 Latency through Regulation of mRNA Levels of Various RUNX1 Isoforms and Increased Tat Expression

NSC95397 is a Novel HIV-1 Latency Reversing Agent

Novel TLR7/8 Agonists Promote Activation of HIV-1 Latent Reservoirs and Human T and NK Cells

Current Status of Latency Reversing Agents Facing the Heterogeneity of HIV-1 Cellular and Tissue Reservoirs

Integrated Single-cell Multiomic Analysis of HIV Latency Reversal Reveals Novel Regulators of Viral Reactivation

Transcription of HIV-1 at sites of intact latent provirus integration

Apoptosis-induced activation of HIV-1 in latently infected cell lines

Nanoparticle delivery of Tat synergizes with classical latency reversal agents to express HIV antigen targets

Targeting Viral Transcription for HIV Cure Strategies

Screening for gene expression fluctuations reveals latency-promoting agents of HIV